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An intricate network regulates the activities of SIRT1 and PARP1 proteins and continues to be uncovered. Both
SIRT1 and PARP1 share a common co-factor nicotinamide adenine dinucleotide (NAD+) and several common
substrates, including regulators of DNA damage response and circadian rhythms. We review this complex network
using an interactive Molecular Interaction Map (MIM) to explore the interplay between these two proteins. Here we
discuss how NAD + competition and post-transcriptional/translational feedback mechanisms create a regulatory
network sensitive to environmental cues, such as genotoxic stress and metabolic states, and examine the role of
those interactions in DNA repair and ultimately, cell fate decisions.
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SIRT1 and PARP1 are enzymes that affect two key post-
translational modifications: acetylation and ADP-ribosylation,
respectively, for a diverse group of proteins. These
enzymes are functionally connected due to their use of a
common substrate, nicotinamide adenine dinucleotide
(NAD+) [1,2]. Recent studies suggest that these proteins
participate in common pathways providing cells with a
mechanism for balancing cell survival and death. A
well-developed understanding of activity overlap of
these proteins may provide insights into the biology
of these two proteins as they are actively being pursued as
therapeutic targets in a range of conditions, including
cancer and metabolic disorders [3-5].
In this review, we look at the role of each of these two
proteins using a Molecular Interaction Map (MIM)
that visually integrates the experimental findings of
the regulatory pathways that surround these proteins,
shown in Figure 1. The MIM helps free readers from
a linear view of events and gain a better understanding
of control loops involved in these pathways [6]. A
machine-readable version of the MIM is provided
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reproduction in any medium, provided the or(http://discover.nci.nih.gov/mim/mim_pathvisio.html) [7].
Additionally, the MIM covers in greater detail the interac-
tions surrounding SIRT1 and PARP1; a complete list of
annotations is also provided as Additional file 2.
Figure 2 shows a modular overview of how the SIRT1
and PARP1 interactions are laid out (an arrow indicates
that a molecule or process from the source module has an
interaction with a molecule or process in the target module)
and Figure 3 provides a legend for reading the MIM
notation. Throughout this review readers will see annotation
labels in double square brackets and prefixed with a letter
that refer to specific interactions in the MIM shown
in Figure 1 and Additional file 2. We focus on aspects
that alter the activity of these proteins, including:
post-translational modifications, co-regulation, NAD +
competition and co-regulated targets. Additionally, we
discuss outstanding questions that would more accurately
describe the relationship between these proteins.
Review
SIRT1
Sirtuins were originally discovered in yeast where the
SIR (Silent Information Regulator) genes are necessary
for the repression of silent mating-type loci [1]. The
mammalian family of sirtuins consists of 7 proteins,
SIRT1-7, which are ubiquitously expressed. Three of the
sirtuins, SIRT1, SIRT6, and SIRT7 localize to the nucleus,
SIRT2 is mainly localized in the cytoplasm, while thed. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 SIRT1 and PARP1 Molecular Interaction Map. Blue: Post-translational modifications, Red: Inhibition and cleavage, Green: Stimulation
and catalysis.
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are found in the mitochondria [8]. The members of
the sirtuin family not only differ in cellular locations,
but also in enzymatic function. SIRT1 and SIRT5 are
primarily protein deacetylases, SIRT4 and SIRT6 are
mono(ADP)-ribosyltransferases, and SIRT2 and SIRT3
exhibit both enzymatic activities; no clear functionality has
been attributed to SIRT 7 [9-14]. The conserved catalyticFigure 2 Modular layout diagram of SIRT1 and PARP1 MIM. Arrows co
to a node in the target module.domain of sirtuins is capable of carrying out both
deacetylation and ADP-ribosylation activities using
NAD+, and it has been suggested that sirtuins may
have the potential to carry out either enzymatic activity
under the right conditions [15,16]. This review will
focus on SIRT1 (EC 3.5.1.-) a member of the sirtuin
family that is expressed in many tissues and acts as a
NAD + −dependent protein deacetylase [1]. SIRT1 hasnnecting modules indicate that a node starting in a module connects
Figure 3 Reference guide for the MIM notation.
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diseases, including: diabetes, cardiovascular disease,
neurodegeneration, cancer, aging, and obesity [17].PARP1
PARP1 (EC 2.4.2.30) is an NAD + −dependent nuclear
ADP-ribosyltransferase with three domains: a DNA
binding domain (DBD), an auto-modification domain
(AD), and a catalytic domain [[A1]] [18]. The PARP family
of proteins are involved in many processes, including: DNA
damage response, cell death, cell cycle regulation, and
telomere regulation [19]. The main function of PARP1
is the formation of poly(ADP-ribose) (PAR) chains on
itself and other proteins [[A2]] [2,20,21]. PARP1 is a
transcriptional co-activator where PAR acts as a signal
helping to regulate transcription [22]. PAR is quickly
cleaved by poly (ADP-ribose) glycohydrolase (PARG)
[[A3]] [20]. PARP1 becomes highly activated by DNAstrand breaks; electrostatic repulsion between the poly
(ADP)-ribose (PAR) chains and DNA eventually leads to
its catalytic inactivation [18].Post-transcriptional regulation of SIRT1 and PARP1
Here we review post-translational modifications that
affect the activities of SIRT1 and PARP1.SIRT1
For a comprehensive review of sirtuin modifications, see
Flick and Luscher [23]. Below we describe several of
these modifications for SIRT1 and augment this list with
additional modifications.
SIRT1 phosphorylation results in both stimulatory and
inhibitory effects. Phosphorylation of SIRT1 by JNK
occurs at three sites: S27, S47, and T530 in response to
oxidative stress that stimulates its deacetylation activity
[[A4]] [24]. In contrast, mTOR also phosphorylates SIRT1
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S47, resulting in the inhibition of SIRT1 [[A5]] suggesting
a multi-site phosphorylation regulatory mechanism is
in place; such a mechanism may be involved in the
regulation of the timing of SIRT1 activity [25,26]. CK2
phosphorylates human SIRT1 at S659 and S661, both
in vivo and in vitro, stimulating its deacetylation activity
[[A4]][27,28]. These two phosphorylation sites exist in a
region of SIRT1 that are essential for SIRT1 activity both
for its catalytic activity and ability to bind to substrates
[29]. Cyclin B/Cdk1, a cell cycle-dependent kinase,
can phosphorylate SIRT1 at T530 and S540 [[A6]].
Phosphorylation at these two sites decreases the activity
of SIRT1 and disrupts progress of the cell cycle [30].
Similar to the case with mTOR and S47, T530 is a
site phosphorylated by JNK and may also function as
a part of a combinatorial modification program.
Kinases DYRK1A and DYRK3 have been shown to
phosphorylate human SIRT1 at T522, stimulating the
deacetylation of p53 by SIRT1[[A7]]; phosphorylation at
this site increases the rate of product release by SIRT1 [31].
AMPK phosphorylates human SIRT1 at T344 inhibiting its
ability to decacetylate p53, a known target of SIRT1 [[A8]]
[32]. In addition to phosphorylation, methylation of SIRT1
by Set7/9 at K233, K235, K236, and K238 inhibits the
SIRT1-mediated deacetylation of p53 in response to DNA
damage [[A9]] [33]. Sumoylation at K734 by SUMO1
increases, whereas desumoylation by SENP1 decreases,
the activity of SIRT1 in response to genotoxic stress
[[A10]] [34]. In this study, genotoxic stress promoted
the association of SIRT1 with SENP1, which may help
to inhibit the ability of SIRT1 to promote survival.
Additionally, transnitrosylation of SIRT1 by GAPDH
at C387 and C390 has been found to inhibit the activity
of SIRT1 leading to decreased PGC1α transcriptional
activity; PGC1α is an important regulator of metabolism
and mitochondrial function [[A11]] [35].
PARP1
The activity of PARP1 can be modulated via post-
translational modifications, including phosphorylation,
sumoylation, and acetylation. DNA-PK phosphorylates
PARP1 though its effect is unknown [[A12]] [36]. Phos-
phorylation of PARP1 by AMPK has been shown to
enhance its activity [[A13]] [37]. This stimulation of PARP1
by AMPK contrasts with the AMPK-mediated inhibition
of SIRT1 and suggests one mechanism by which AMPK,
a metabolic sensor able to regulate ATP-consuming
pathways, may be capable of controlling cell survival
given the roles of PARP1 and SIRT1 in response to DNA
damage. ERK1/2 has also been shown to phosphorylate
PARP1 in neuronal cells and to stimulate the activity of
PARP1 in response to DNA damage; inhibition of ERK1/2
results in the inhibition of PARP1-mediated cell death[38]. PARP1 is acetylated by p300/CBP; this acetylation is
involved in the activation of NF-κB by PARP1 [[A14]] [39].
PARP1 is sumoylated by SUMO1 and SUMO3 at K486 of
PARP1's auto-modification domain. This modification
inhibits the ability of p300 to acetylate PARP1 and inhibits
the expression of genes that are transcriptionally targeted
by PARP1 [[A15]] [40].
Co-regulation of SIRT1 and PARP1
Cross-modification and transcriptional co-regulation
SIRT1 and PARP1 are transcriptionally and functionally
interconnected [41-43]. In SIRT1-deficient mouse cardio-
myocytes, Rajamohan et al. in 2009 found increased levels
of PARP1 acetylation in response to mechanical stress,
suggesting that SIRT1 can deacetylate PARP1 [[A16]] [44].
Whether this interaction occurs during genotoxic stress
or other types of stresses remains an open question. No
similar modification reaction has been seen on SIRT1 by
PARP1 in response to DNA damage. However, SIRT1 is
able to negatively regulate the PARP1 promoter, and the
SIRT1 promoter has been shown to be under the influence
of PARP2 [45,46].
NAD + competition
Another key co-regulatory mechanism between these two
proteins is the utilization of nicotinamide adenine dinucleo-
tide (NAD+). It has been suggested by several studies that
activation of PARP1 causes a depletion in NAD+ levels,
which inhibits SIRT1 activity [42-45]. In mammals, NAD+ is
mainly generated through the salvage pathway; this pathway
involves nicotinamide (NAM) as the major precursor in this
multi-step process that involves the conversion of
NAM into nicotinamide mononucleotide (NMN) and
then NMN into NAD+. The rate-limiting protein in the
NAM-NMN-NAD+ conversion is nicotinamide phosphor-
ibosyltransferase (NAMPT) [[A17]]. PARP1 was shown to
have a greater effect on NAD+ depletion than SIRT1 in
response to the NAMPT inhibitor, FK866 [47]. In a related
study, the inhibition of NAMPT by FK866 was shown to
produce an effect similar to SIRT1 depletion [48].
Recent evidence suggests that local supplies of
NAD+may be important for the enzymatic activities of
these two proteins, shown in Figure 4 [49-51]. Nicotinamide
mononucleotide adenylyltransferase 1 (NMNAT1), which
catalyzes the conversion of NMN into NAD + in the
synthesis of NAD+ via the salvage pathway, can bind to
(ADP-ribose) polymers in vitro leading to the stimulation of
PARP1 activity; this effect is diminished when NMNAT1 is
phosphorylated at S136 by protein kinase C (PKC) [[A18]]
[52]. A similar interaction has been shown to occur
with SIRT1, whereby SIRT1 binds to NMNAT1 helping to
recruit NMNAT1 to specific promoters, which may help
stimulate SIRT1 activity [[A19]] [53]. PARP1 activity leads
to increased NAM concentrations at DNA damage sites,
Figure 4 The effect of NMNAT1 binding on SIRT1 and PARP1 activity. Zhang et al. proposed that NMNAT1 may stimulate SIRT1 activity;
indicated by the dashed line.
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deacetylase activity [54]. Further work is needed to
understand the function of these two proteins around
chromatin sites occupied beforehand by one of them.
Regulation of common SIRT1 and PARP1 targets
SIRT1/PARP1 response to DNA damage
DNA damage response to both endogenous and exogenous
sources is an intricate process that is not fully understood
due to the complexity of the potential lesions, the number
of proteins involved in both surveillance and repair,
the interconnected regulation of proteins involved in
the detection and repair of damage, stoppage of the cell
cycle, and the potential induction of cell death; reviewed
by [55]. SIRT1 and PARP1 play several roles throughout
the response to DNA damage from the initial response to
final cell fate decisions.
Histones
Both SIRT1 and PARP1 are known to modify histones;
deacetylation of histones triggers chromatin compaction
and the inhibition of transcription, whereas poly
(ADP-ribose) polymers help to relax chromatin. SIRT1 is
capable of deacetylating several histone amino acid resi-
dues, including H1K26, H3K9, H3K14, and H4K16 [[A20]]
[56,57], while PARP1 can modify histones H1, H2AK13,
H2BK30, H3K27, H3K37, and H4K16 to possibly regulate
transcription [[A21]] [21,58]. It has been suggested that
ADP-ribosylation of histone H1 promotes transcription by
inhibiting the ability of histone H1 to bind to DNA [59].
Additionally, a competitive interaction has been shown
between acetylation and PAR where acetylation of
H4K16 inhibits the ADP-ribosylation of histone H4
[[A22]] [21]. Here a potential contradiction in the role of
SIRT1 in condensing chromatin arises whereby SIRT1deacetylation activity could potentially help drive the
PARP1 ADP-ribosylation activity on H4K16. Currently, it
is known that SIRT1 plays a role in DNA damage repair
via histone deacetylation through the deacetylation of the
two histone acetyltransferases, TIP60 and MOF, which are
able to acetylate histone H4 [[A23]]. Deacetylation of
these two proteins promotes their ubiquitin-dependent
degradation affecting DNA double-strand break (DSB)
repair either through the repression of repair or affecting
the choice of repair mechanism (i.e. homologous recombin-
ation or non-homologous end joining (NHEJ)) [60-63].
TIP60-dependent acetylation of H4K16 inhibits the binding
of 53BP1 to H4K20me2, which promotes non-homologous
end joining [[A24]] [62,64]. Further studies are needed to
understand how DNA damage might affect modifications
on the various histones though it is known that genotoxic
stress causes a random redistribution of SIRT1 across the
genome with a correlated increase in levels of H1K26
acetylation [65]. However, while PARP1 does localize to
DNA strand breaks, it is also not known whether there is
any further global redistribution PARP1 or a relationship to
the redistribution of SIRT1.
DNA damage signaling pathway
Both SIRT1 and PARP1 are DNA damage responders and
the absence of either of these proteins may lead to
DNA damage sensitization [66,67]. PARP1 begins to
localize to DNA breaks rapidly and becomes activated
by binding to DNA breaks. The ADP-ribosylation activity
of PARP1 increases 10–500 fold as a result of binding
to DNA breaks [[A25]] [2]. Once activated, PARP1 may
help repair single strand DNA breaks, preventing their
conversion to double-stranded breaks [[A26]] [68]. In
addition, PARP1 is involved in DNA repair through its
associations with base excision repair (BER) enzymes
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by helping these proteins localize to sites of DNA
damage [[A27]] [69].
Two early responders of DNA damage linked to SIRT1
and PARP1 regulation are ATM (ataxia telangiectasia,
mutated) and CHK2 (checkpoint kinase 2) [70]. The
activation of ATM by DNA breaks requires the acti-
vation of the MRE11-RAD50-NBS1 (MRN) complex
[[A28-A30]]. It has been shown that PARP1 binds to
ATM, an interaction that is stimulated by DNA damage,
and that the automodification of PARP1 leads to ATM
activation [[A31]] [67].
An extended feedback loop has been proposed by
Gorospe and de Cabo involving SIRT1 and several
key DNA damage repair proteins [70]. In this loop,
NBS1 is phosphorylated by ATM in response to genotoxic
stress at S343 for the activation of NBS1; to be phosphory-
lated, it is necessary for NBS1 to be in a hypoacetylated
state, which SIRT1 helps to maintain by deacetylating
NBS1 [[A32-A33]] [71,72]. CHK2 is activated when T68 is
phosphorylated by ATM. CHK2 can then phosphorylate
HuR at several sites causing it to dissociate from SIRT1
mRNA, and thereby reduce the half-life of the SIRT1
mRNA [[A34]] [73]. It has been suggested that in repairable
DNA damage situations SIRT1 levels are elevated leading
to a survival response, but during lethal DNA damage
SIRT1 levels can be attenuated by CHK2 through the
phosphorylation of HuR that can ultimately result in
cell death [70].
SIRT1 is also regulated by c-MYC and E2F1, two proteins
involved in cell proliferation, differentiation and apoptosis,
through negative feedback loops shown in Figure 5. E2F1, a
transcription factor, induces the transcription of SIRT1
[[A35]]. Conversely, E2F1 has been suggested to be a target
for SIRT1 deacetylation, which inhibits E2F1 activity
[[A36-A37]] [74]. Additionally, the transcriptional activity
of E2F1 is inhibited by Retinoblastoma (Rb), which isFigure 5 Interactions between SIRT1 and transcription factors c-MYC
from Yuan, Minter-Dykhouse et al. 2009 forming a negative feedback loop, wh
Hydbring et al. 2012.another substrate of SIRT1 deacetylation; acetylation of
Rb has been shown to regulate the binding of Rb to E2F1
[[A38]] [75,76]. Two studies have examined the interac-
tions between SIRT1 and c-MYC producing contradictory
results. In one publication, c-MYC over-expression leads
to an increase in SIRT1 expression and then deacetylation
of c-MYC by SIRT1 leads to the destabilization of c-MYC
[[A39]] [77]. In the second publication, neither the
induction of SIRT1 expression nor the destabilization
of c-MYC was seen following c-MYC activation. Instead, a
stabilizing effect on c-MYC due to deacetylation by SIRT1
was found. Also in the second study, Menssen et al. found
that c-MYC can induce the transcription of NAMPT and
help sequester DBC1, an inhibitor of SIRT1 [[A40]] [78].
Another line of evidence suggesting that SIRT1 may affect
NAMPT through a second mechanism involving the
circadian clock will be discussed later. There is evidence
that PARP1 binds to E2F1 stimulating E2F1-dependent
transcription of c-MYC [[A41]] [79]. This presents the
possibility that both SIRT1 and PARP1 may be capable of
influencing the regulation of NAMPT to affect NAD+ levels
through c-MYC.
Another co-regulated protein is NF-κB, a regulator of
cellular response, including inflammation, to stress. In
the case of NF-κB, the effects of SIRT1 and PARP1 are
opposing. SIRT1 can deacetylate the RelA/p65 subunit
of NF-κB at K310 to inhibit NF-κB transactivation activ-
ity [[A42]] [80]. PARP1 is an activator of NF-κB through
its direct binding to NF-κB; acetylation of PARP1 by
p300/CBP is required for the binding of PARP1 to
NF-κB [[A43]] [39].
Given the importance of p53 to apoptotic response, a
number of studies have focused on the regulation of p53
by SIRT1. p53 acts as a transcription factor that induces
apoptosis and is inhibited by SIRT1 deacetylation [[A44]]
[81,82]. SIRT1 has the capability of deacetylating p53 at
several sites in mouse embryonic fibroblasts (MEFs) andand E2F1. Solid lines between SIRT1 and c-MYC indicated are interactions
ile dashed lines are findings related to SIRT1 and c-MYC from Menssen,
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precise role of p53 acetylation is unclear [[A45]] [83-85].
Several proteins help to modify the interactions of SIRT1
with p53, including p53 (itself ), DBC1, AROS, and HIC1,
suggesting that it is a cellular imperative to control the
inhibition of p53 by SIRT1 under certain conditions. p53
can repress SIRT1 expression during nutrient abundance
via p53-binding sites on the SIRT1 promoter. This
effect is countered by the transcription factor FOXO3A,
which interacts with p53 in an inhibitory fashion during
nutrient deprivation [[A46-A47]] [86,87]. Hypermethylated
in cancer-1 (HIC1) is a transcriptional repressor of the
SIRT1 promoter [[A48]] that helps prevent age-dependent
cancers in mice. If HIC1 is inhibited, SIRT1 expression
increases, allowing for more efficient inactivation of p53;
p53 over-expression leads to the transactivation of HIC1,
thus creating a negative feedback loop [88].
Micro-RNAs have also been shown to downregulate
SIRT1-dependent deacetylation of p53. p53 can stimulate
the expression of miRNA-34 [[A49]], which subsequently
drives down the expression of SIRT1 lowering SIRT1
availability to inhibit p53. Over 15 micro-RNAs affect
the expression of SIRT1 either directly or by decreasing
the expression of HuR, which stabilizes SIRT1 mRNA
[[A50]] [89,90].
Given the well-studied nature of p53 as a SIRT1 substrate,
p53 has been used to characterize SIRT1 inhibitors and
activators. In humans, deleted in breast cancer 1 (DBC1)
acts as an inhibitor of SIRT1 (an inhibitory effect increased
by the phosphorylation of DBC1) and whose effect
has been shown to lead to p53 hypoacetylation [[A51-A52]]
[29,91-93]. Active Regulator of SIRT1 (AROS) has been
shown to bind SIRT1 and help enhance the deacetylation
of p53 by SIRT1 [[A53]] [94]. Further studies are needed to
understand if the effects on p53 acetylation states are
specific to the activities of DBC1 and AROS on SIRT1 or if
other substrates of these two proteins are involved.
Much less is known about the interaction between
PARP1 and p53. PARP1 helps p53 accumulate in the
nucleus by (ADP-ribosyl)ating p53, which prevents p53
nuclear export [95], and there is evidence to suggest that
SIRT1 deacetylation activity is capable of blocking p53
nuclear translocation [96].
Cell death
In addition to the role that SIRT1 plays in the inhibition
of p53, SIRT1 is capable of deacetylating Ku70 at K539
and K542; the acetylation of Ku70 leads to the dissociation
of the Ku70 and Bax helping to trigger apoptosis; Bax is a
pro-apoptotic factor that is sequestered by Ku70
[[A54-A55]] [97]. NBS1, which we have discussed here
beforehand as being activated via deacetylation by SIRT1,
has also been shown to help control the interaction
between Ku70 and Bax by stimulating the acetylation ofKu70 [[A56]] [98]. The exact conditions leading to a
differential role of SIRT1 on the Ku70 and Bax complex
remains to be uncovered.
PARP1 plays a role in cell death pathways (apoptosis
or necrosis) in the course of responding to DNA damage.
ATP is required for optimal caspase activation, and the
depletion of ATP can direct cells between apoptotic and
necrotic pathways [99]. During normal apoptosis, PARP1
is cleaved by caspases; the role of these cleaved fragments
play is not fully understood [[A57]]. PARP1 cleavage helps
prevent energy depletion (NAD+ and ATP) in response to
severe DNA damage; the extreme loss of NAD + triggers
necrosis by reducing cellular ability to synthesize ATP
[[A58]] [100]. Cells with severe DNA damage die from
necrosis because they are not able to switch away from the
necrotic pathway since the kinetics of NAD+ depletion are
faster than those of PARP1 cleavage [2]. Rapid depletion of
NAD+ levels by PARP1 reduces SIRT1 activity and inhibits
the capability of SIRT1 to deacetylate its targets respond to
genotoxic stress [101]. PARP1 has also been implicated in
caspase-independent apoptosis, where its activation
leads to apoptosis-inducing factor (AIF) release from
the mitochondria, which induces nuclear chromatin
fragmentation [[A59]] [102].
Circadian rhythms
Recent SIRT1 and PARP1 research has uncovered roles
for the two proteins in circadian rhythms creating the
possibility for novel interconnections between metabolism,
DNA repair, and circadian rhythms (Figure 6). The
core circadian machinery involves a transactivating
CLOCK/BMAL1 heterodimer, which induces the transcrip-
tion of a large number of genes, including the crypto-
chrome (CRY1 and CRY2) and period (PER1, PER2, PER3)
genes that form a complex that leads to a negative feedback
loop suppressing CLOCK/BMAL1-mediated transcription
[[A60-A62]]. Several studies have shown that disruptions in
core circadian interactions can lead to alterations in DDR;
reviewed in [103].
SIRT1 deacetylates BMAL1 at K537 destabilizing the
interaction between CRY and BMAL1 [[A63]] [104,105].
CLOCK possesses acetyltransferase activity that regulates
the transcriptional activity of CLOCK/BMAL1 [106] and
is capable of acetylating some of the same locations that
SIRT1 deacetylates: H3K9, H3K14, and BMAL1 at K537
[[A64]] [57,105]. SIRT1 has also been shown to deacetylate
PER2 destabilizing the protein [[A65]]; it has been hypothe-
sized that acetylation of PER2 at lysine residues prevents
their ubiquitination [107]. This presents a dual control
mechanism for SIRT1 in the circadian clock where it is cap-
able of balancing transcription through chromatin conden-
sation, but also by disrupting the ability for CRY and
PER2 to repress CLOCK/BMAL1 activity. SIRT1 is
involved in NAMPT transcriptional regulation, which
Figure 6 Interactions of SIRT1 and PARP1 with circadian clock components.
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as a consequence of NAMPT level oscillation [48,108].
Additionally, it has been shown that PARP1 has rhythmic
activity influenced by feeding patterns though further work
is necessary to understand the underlying molecular
mechanism. PARP1 is capable of ADP-ribosylating CLOCK
in a circadian manner disrupting the association between
the BMAL1/CLOCK heterodimer and its targets [[A66]]
[109]. It remains to be determined whether a regulatory
effect exists between SIRT1 or PARP1 and the circadian
components during DNA damage.
Interactions with other family members
While the focus of this review has been on the inter-
relationships that exist between SIRT1 and PARP1, there
is growing evidence that SIRT1 has the capability of
interacting with other members of the PARP family of
proteins and similarly that PARP1 is capable of interacting
with multiple sirtuins. Here we present three cases of
these interactions; these interactions range include both
direct modifications, as well as transcriptional regulation.
First, SIRT6, one of the nuclear sirtuins, plays a role in
promoting DNA damage repair by binding and activating
PARP1 by mono-ADP-ribosylating PARP1 triggering its
auto-ADP-ribosylation activity [[A67]] [110]. Next, the
second PARP family member, PARP2, has been shown to
inhibit the transcription of SIRT1; the deletion of PARP2
increases overall levels of SIRT1 activity without having to
target NAD + levels directly [[A68]] [46]. This finding
indicates that inhibitors of PARP proteins may be
capable of increasing SIRT1 activity not only via the inhib-
ition of NAD + consumption by PARP family members,
but also through the removal of transcriptional inhibition.
Lastly, shown recently is that PARP1 increases levels ofmitochondrial SIRT3 and that SIRT3 can continue to
function under stress conditions because mitochondrial
NAD+ levels are maintained in the conditions produced by
either treatment with methylnitronitrosoguanidine (MNNG),
a carcinogen, or N-methyl-D-aspartate (NMDA), a neuronal
stressor, even as cytosolic levels of NAD+ are depleted by
PARP1 [111,112]. This study by Kim et al., did not observe a
similar change in SIRT1 protein levels or the expression
levels of the other mitochondrial sirtuins, SIRT4 and SIRT5.
Conclusions
Cells respond to DNA damage through coordinated
pathways that arrest the cell cycle and repair the
damage, and in the presence of severe damage trigger
cell death. Both SIRT1 and PARP1 play an intimate
role in the regulation of genomic stability, and continued
work is necessary for the understanding of the specific con-
texts in which modulators of SIRT1 and PARP1 activity
may be appropriate as therapeutics for cancer and metabolic
disorders. The regulation of SIRT1 and PARP1 is controlled
by a variety of stimuli, including metabolic, circadian, and
genotoxic. Understanding how each of these stimuli affects
the regulatory network of these two proteins is vital.
The work of the past several years has trended towards
an understanding of the diverse regulatory network
surrounding these two proteins, the effects of local levels
of their common substrate, NAD+, and the co-regulation
of and by the two proteins. There continue to be several
unexplored areas. For example, understanding the nature
of competitive regulation of acetylation and PAR at a single
substrate residue on a single molecule, since both can target
lysine residues, remains an open area of research. Another
interesting avenue of research remaining to be thoroughly
explored is the alteration of the reviewed pathways as an
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increases in DNA damage can lead to NAD+ depletion
[113,114]. In human tissue samples, Massudi et al. found
an age-related positive correlation in PARP1 activity in
males and negative correlations with SIRT1 activity in
males and NAD+ levels in both males and females that
starts to shed light on the role of these two proteins in the
presence of accumulating DNA damage with age [114]. In
a related study, Chang et al. showed a reduction in SIRT1
levels over time resulting in alterations in circadian oscilla-
tions in mice as they age [115]. Studies such as these sug-
gest that the regulatory network surrounding SIRT1 and
PARP1 may undergo large-scale changes over an organism’s
lifespan; currently, we do not know the extent of these
changes. Additionally, there is a deficit in our knowledge
with respect to the influence that DNA damage response
may have on circadian regulation and vice versa and the
roles that SIRT1 and PARP1 may play. And while this re-
view has focused on evidence of the interactions between
the better studied members of their respective protein fam-
ilies, SIRT1 and PARP1, additional work is necessary in our
understanding of the roles of the other members of
the two protein families and their unique properties
and interactions that may play integral roles in the
progression of DDR, as well as other processes.
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